Mersana Therapeutics (MRSN) Stock Forecast & Price Target

$2.12

+0.08 (+3.92%)

(As of 09/18/2024 ET)

Mersana Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy
Based on 8 Analyst Ratings

Based on 8 Wall Street analysts who have issued ratings for Mersana Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 8 analysts, 2 have given a hold rating, 5 have given a buy rating, and 1 has given a strong buy rating for MRSN.

Consensus Price Target

$6.00
183.02% Upside

High Forecast	$9.00
Average Forecast	$6.00
Low Forecast	$3.00

According to the 8 analysts' twelve-month price targets for Mersana Therapeutics, the average price target is $6.00. The highest price target for MRSN is $9.00, while the lowest price target for MRSN is $3.00. The average price target represents a forecasted upside of 183.02% from the current price of $2.12.

Type	Current Forecast 9/19/23 to 9/18/24	1 Month Ago 8/20/23 to 8/19/24	3 Months Ago 6/21/23 to 6/20/24	1 Year Ago 9/19/22 to 9/19/23
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Reduce
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	5 Buy rating(s)	5 Buy rating(s)	5 Buy rating(s)	0 Buy rating(s)
Hold	2 Hold rating(s)	2 Hold rating(s)	2 Hold rating(s)	6 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$6.00	$6.00	$6.29	$8.57
Forecasted Upside	183.02% Upside	52.67% Upside	41.89% Upside	102.04% Upside

This diversified cannabis pioneer could make huge moves soon (Ad)

The cannabis industry seems deeply saturated, so how do you know where to best invest your money? Let’s start with diversification and experience. Founded in 2005, this company serves a diverse and expansive customer base with more than 8,000 retail locations, including licensed cannabis dispensaries, smoke shops, and specialty retailers.

Learn more here.

MRSN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

MRSN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Mersana Therapeutics Stock vs. The Competition

Type	Mersana Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.88	2.77	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	183.02% Upside	1,009.48% Upside	7.94% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
8/27/2024	Citigroup 3 of 5 stars		Lower Target	Buy ➝ Buy	$6.00 ➝ $5.00	+217.46%
8/14/2024	Robert W. Baird 2 of 5 stars		Lower Target	Neutral ➝ Neutral	$4.00 ➝ $3.00	+122.22%
7/29/2024	Lifesci Capital 2 of 5 stars	C. Zhu Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
3/19/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Underweight ➝ Neutral	$5.00	+2.88%
2/29/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy	$9.00	+85.57%
2/29/2024	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$6.00	+23.71%
This diversified cannabis pioneer could make huge moves soon (Ad) The cannabis industry seems deeply saturated, so how do you know where to best invest your money? Let’s start with diversification and experience. Founded in 2005, this company serves a diverse and expansive customer base with more than 8,000 retail locations, including licensed cannabis dispensaries, smoke shops, and specialty retailers. Learn more here.
2/29/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$7.00	+44.33%
2/29/2024	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Nierengarten Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Outperform	$2.00 ➝ $7.00	+44.33%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 10:51 PM ET.

MRSN Forecast - Frequently Asked Questions

What is Mersana Therapeutics' forecast for 2024?: According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for Mersana Therapeutics is $6.00, with a high forecast of $9.00 and a low forecast of $3.00.
Should I buy or sell Mersana Therapeutics stock right now?: 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Mersana Therapeutics in the last twelve months. There are currently 2 hold ratings, 5 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" MRSN shares.
Does Mersana Therapeutics's stock price have much upside?: According to analysts, Mersana Therapeutics's stock has a predicted upside of 54.50% based on their 12-month stock forecasts.
Has Mersana Therapeutics been upgraded by Wall Street analysts recently?: Over the previous 90 days, Mersana Therapeutics's stock had 1 upgrade by analysts.
What analysts cover Mersana Therapeutics?: Mersana Therapeutics has been rated by research analysts at Citigroup, Lifesci Capital, and Robert W. Baird in the past 90 days.
Do Wall Street analysts like Mersana Therapeutics more than its competitors?: Analysts like Mersana Therapeutics more than other "medical" companies. The consensus rating score for Mersana Therapeutics is 2.88 while the average consensus rating score for "medical" companies is 2.77. Learn more on how MRSN compares to other companies.